Yizhe Chen

5PUBLICATIONS
24CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPharmaceutical delivery technologiesNanochemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

|Jun 09, 2025
Exposure-response relationship of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

Yizhe Chen, Yan Li, Yongjun Xue

|Aug 07, 2024
Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19.

Ming Chang, Yizhe Chen, Ken Ogasawara

|Nov 13, 2023
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults.

Yizhe Chen, David Wyatt, Massimo Attanasio

|Jun 06, 2017
Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase.

Daniel C Scott, Jared T Hammill, Jaeki Min

Pageof 1

Frequent Collaborators

3 joint publications

Ken Ogasawara

1 joint publications

David Y Rhee

1 joint publications

Joao A Paulo

1 joint publications

Anang A Shelat